On why Pfizer Korea filed a “tax appeal” against the National Tax Service, the company said it had “duly instituted administrative procedures, judging that some of the imposed taxation standards were unreasonable,” refuting the allegations that the company was fined due to ‘cost overstatements.’

According to the pharmaceutical industry on the 26th, the National Tax Service levied fines on some Korean subsidiaries of multinational pharmaceutical companies including Pfizer Korea after tax audits. Pfizer Korea did not disclose the specifics on its amount, but the amount is estimated to be in the tens of billion won range.

Pfizer Korea filed a tax appeal regarding the additional fine l